Compare Prologis Inc (PLD) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prologis Inc vs ResMed Inc. — how do they compare? Prologis Inc trades at $144.35 (market cap $139.79B), while ResMed Inc. trades at $193.21 (market cap $28.40B). The key difference: Prologis Inc is far larger — about 4.9× ResMed Inc.'s market cap, and Prologis Inc pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| PLD | RMD | |
|---|---|---|
Market Cap | $139.79B | $28.40B |
Sector | Real Estate | Health |
52-Week High | $149.96 | $293.73 |
52-Week Low | $104.08 | $182.82 |
Enterprise Value | $174.47B | $27.58B |
Dividend Yield | 2.85% | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLD trades at $149.94, up 0.15% with a bullish technical outlook. The stock shows strong fundamentals with revenue growth to $8.79B in 2025 and a net income margin of 45.79%. Recent Q2 2026 earnings beat expectations, and analyst consensus is positive with a $156.56 price target. The company is actively pursuing acquisition opportunities, as seen in recent Segro takeover attempts.
The outlook for PLD remains favorable due to consistent earnings beats and strategic expansion. Key risks include high valuation multiples and integration challenges from potential acquisitions. Institutional ownership is increasing, supporting a bullish sentiment, though investors should monitor debt levels which have risen to 37.2% of assets in 2025.
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
